KR100614361B1 - 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법 - Google Patents

남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법 Download PDF

Info

Publication number
KR100614361B1
KR100614361B1 KR1020027008845A KR20027008845A KR100614361B1 KR 100614361 B1 KR100614361 B1 KR 100614361B1 KR 1020027008845 A KR1020027008845 A KR 1020027008845A KR 20027008845 A KR20027008845 A KR 20027008845A KR 100614361 B1 KR100614361 B1 KR 100614361B1
Authority
KR
South Korea
Prior art keywords
delete delete
composition
prostaglandin
weight percent
erectile dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027008845A
Other languages
English (en)
Korean (ko)
Other versions
KR20020073498A (ko
Inventor
제임스 이거
나디르 부육팀킨
세르베트 부육팀킨
Original Assignee
넥스메드 홀딩스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23909154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100614361(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 넥스메드 홀딩스 인코포레이티드 filed Critical 넥스메드 홀딩스 인코포레이티드
Publication of KR20020073498A publication Critical patent/KR20020073498A/ko
Application granted granted Critical
Publication of KR100614361B1 publication Critical patent/KR100614361B1/ko
Assigned to 페링 인터내셔널 센터 에스 에이 reassignment 페링 인터내셔널 센터 에스 에이 권리의 전부이전등록 Assignors: 넥스메드 홀딩스 인코포레이티드
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020027008845A 2000-01-10 2001-01-10 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법 Expired - Lifetime KR100614361B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/480,738 2000-01-10
US09/480,738 US6323241B1 (en) 2000-01-10 2000-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (2)

Publication Number Publication Date
KR20020073498A KR20020073498A (ko) 2002-09-26
KR100614361B1 true KR100614361B1 (ko) 2006-08-18

Family

ID=23909154

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027008845A Expired - Lifetime KR100614361B1 (ko) 2000-01-10 2001-01-10 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법

Country Status (20)

Country Link
US (1) US6323241B1 (https=)
EP (1) EP1255552B1 (https=)
JP (2) JP2003519657A (https=)
KR (1) KR100614361B1 (https=)
CN (1) CN1394140A (https=)
AT (1) ATE290383T1 (https=)
AU (1) AU760576C (https=)
BE (1) BE2014C001I2 (https=)
BR (1) BR0107478A (https=)
CA (1) CA2395217C (https=)
DE (1) DE60109274T2 (https=)
ES (1) ES2236245T3 (https=)
HK (1) HK1047700B (https=)
HU (1) HUP0204159A3 (https=)
IL (2) IL150306A0 (https=)
MX (1) MXPA02006758A (https=)
PT (1) PT1255552E (https=)
TR (1) TR200201769T2 (https=)
WO (1) WO2001051053A1 (https=)
ZA (1) ZA200205433B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
DK1474143T3 (da) 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
MXPA04007828A (es) * 2002-02-15 2004-10-15 Nexmed Holdings Inc Composicion de prostaglandina para eltratamiento de la disfuncion erectil.
CA2493723A1 (en) * 2002-09-06 2004-03-18 Nexmed Holdings, Inc. Methods of treatment of male erectile dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
BRPI0408454A (pt) 2003-03-21 2006-04-04 Nexmed Holdings Inc composição tópica, método de tratar a ejaculação precoce, e, uso da composição
KR20050119134A (ko) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 발기 부전 치료용 프로스타글란딘 조성물
JP2006520788A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物による血管形成促進および方法
AU2004227853A1 (en) * 2003-04-02 2004-10-21 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
EP1784225B1 (en) * 2004-08-19 2016-10-05 Applied Genetics Incorporated Dermatics Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
EP2646015B1 (en) * 2010-12-02 2020-04-22 Ferring International Center S.A. Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
EP3266458A1 (en) 2016-07-05 2018-01-10 Fagron B.V. Method and composition and kit for treating erectile dysfunction
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine
USD1122263S1 (en) * 2023-02-15 2026-04-14 Amadeus S.A.S. Display screen with animated graphical user interface

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
PT97441B (pt) 1990-04-25 1998-08-31 Alza Corp Processo para a preparacao de composicoes farmaceuticas que compreendem agentes vasodilatadores, nomeadamente, nitratos, alcaloides ergoticos ou prostaglandinas, ou agentes vasoconstritores, nomeadamente, alcoois benzilicos ou benzenodiois substituidos ou ainda agentes antiflamatorios esteroides e nao esteroides e dispositivos para a sua administracao transuretral
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
NZ305560A (en) 1995-03-14 1998-11-25 Vivus Inc Method for preventing erectile dysfunction by administering vasoactive agent, particularly a prostaglandin, kit therefor
AU742787B2 (en) * 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis

Also Published As

Publication number Publication date
JP2007302690A (ja) 2007-11-22
IL150306A0 (en) 2002-12-01
AU760576B2 (en) 2003-05-15
EP1255552B1 (en) 2005-03-09
BE2014C001I2 (https=) 2020-01-30
IL150306A (en) 2007-06-03
PT1255552E (pt) 2005-06-30
HK1047700B (en) 2005-05-27
DE60109274D1 (de) 2005-04-14
ZA200205433B (en) 2003-11-26
US6323241B1 (en) 2001-11-27
CA2395217C (en) 2004-10-26
TR200201769T2 (tr) 2002-11-21
EP1255552A1 (en) 2002-11-13
HUP0204159A3 (en) 2005-03-29
HK1047700A1 (en) 2003-03-07
CN1394140A (zh) 2003-01-29
AU2934901A (en) 2001-07-24
BR0107478A (pt) 2002-09-03
KR20020073498A (ko) 2002-09-26
DE60109274T2 (de) 2006-02-09
CA2395217A1 (en) 2001-07-19
HUP0204159A2 (hu) 2003-04-28
WO2001051053A1 (en) 2001-07-19
JP2003519657A (ja) 2003-06-24
AU760576C (en) 2004-04-08
MXPA02006758A (es) 2008-09-12
ES2236245T3 (es) 2005-07-16
ATE290383T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
KR100614361B1 (ko) 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법
US6693135B2 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
AU2002323650A1 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
US11246932B2 (en) Prostaglandin compositions and methods for the treatment of vasospasm
KR20040082431A (ko) 발기기능장애를 치료하기 위한 프로스타글란딘 조성물
TWI324930B (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020709

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050221

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060705

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060811

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060810

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090612

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100520

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110530

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20120725

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20120725

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130725

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130725

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140724

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140724

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150727

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150727

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160727

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160727

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170719

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180802

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180802

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190813

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190813

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20200729

Start annual number: 15

End annual number: 15

PC1801 Expiration of term

Termination date: 20210710

Termination category: Expiration of duration